BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
US Department of Justice
Harvard Business School
Boehringer Ingelheim

Generated: March 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,890,949

« Back to Dashboard

Title: Amino ceramide-like compounds and therapeutic methods of use
Abstract:Novel amino ceramide-like compounds (1) are provided which inhibit glucosyl ceramide (GlcCer) formation by inhibiting the enzyme GlcCer synthase, thereby lowering the level of glycosphingolipids. The compounds of the present invention have improved GlcCer synthase inhibition activity and are therefore highly useful in therapeutic methods for treating various conditions and diseases associated with altered glycosphingolipid levels.
Inventor(s): Shayman; James A. (Ann Arbor, MI), Radin; Norman S. (Menlo Park, CA)
Assignee: The Regents of the University of Michigan (Ann Arbor, MI)
Filing Date:Jan 09, 2002
Application Number:10/030,963
Claims:1. A method for treating a patient having a microbial or viral infection comprising the step of administering to the patient a therapeutically effective amount of a compound selected from the group consisting of D-t-3', 4'-ethylenedioxy-1-phenyl-2-palmitoylamino-3-pyrrolidino-1-propanol, D-t-4'-hydroxy-1-phenyl-2-palmitoylamino-3-pyrrolidino-1-propanol and stereoisomers and pharmaceutically acceptable salts thereof, wherein the infection is characterized by binding of the microbe, the virus, or a toxin thereof to glycosphingolipids of the patient's cells.

2. The method of claim 1, wherein the infection is due to E. Coli, influenza A, or a verotoxin-producing microorganism.

3. The method of claim 1, wherein compound is D-t-3', 4'-ethylenedioxy-1-phenyl-2-palmitoylamino-3-pyrrolidino-1-propanol, or a pharmaceutically-acceptable salt thereof.

4. The method of claim 1, wherein the compound is D-t-4'-hydroxy-1-phenyl-2-palmitoylamino-3-pyrrolidino-1-propanol, or a pharmaceutically-acceptable salt thereof.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Fish and Richardson
Boehringer Ingelheim
US Army
Johnson and Johnson
Federal Trade Commission
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.